Lewis y is a difucosylated
oligosaccharide carried by
glycoconjugates on the cell surface. Elevation of Lewis y is frequently observed in epithelial-derived
cancers. This study aimed to detect the expression and clinical significance of the
Lewis y antigen and TGF-β1 (
transforming growth factor β1) in ovarian epithelial
tumors, and to evaluate the correlation between them. Immunohistochemical staining was used to detect the expression of
Lewis y antigen and TGF-β1 in 60 cases of ovarian epithelial malignant
tumors, 20 cases of borderline ovary
tumors, 20 cases of benign ovary
tumors and 10 cases of normal ovarian tissues. An immunofluorescence double labeling method was also used to detect the correlation between
Lewis y antigen and TGF-β1. The positive rates of
Lewis y antigen in
ovarian epithelial cancer tissues was 88.33%, significantly higher compared to those of borderline ovarian
tumors (60.00%) (P<0.05), benign ovarian
tumors (35.00%) (P<0.01) and normal ovarian tissues (0%) (P<0.01). Its expression was not associated with clinical parameters; the positive rates of TGF-β1 in
ovarian epithelial cancers were 78.33%, significantly higher compared to those of benign ovarian
tumors (65.00%) (P<0.05) and normal ovarian tissues (40.00%) (P<0.05); the positive rates of the TGF-β1 and Lewis y were not associated with
metastasis of lymph nodes and histological types, differentiation degree and clinical stage (P>0.05). Expression of
Lewis y antigen and TGF-β1 was significantly positively associated with epithelial
carcinoma. Close correlation between Lewis y, TGF-β1 and
ovarian cancer was observed. Altered expression of
Lewis y antigen may cause changes in TGF-β1 expression. Lewis y can increase the growth of
ovarian cancer cells and the invasion ability by promoting TGF-β1 abnormal expression and by promoting angiogenesis and a change in its signal transduction pathway. This study provides theoretical evidence for the development of
ovarian cancer biological treatments.